Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer immune cell trial halted after just 2 patients

NCT ID NCT06235242

Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early trial tested a treatment that takes immune cells from a patient's own tumor, grows them in a lab, and gives them back along with an immune-boosting drug called teraplizumab. The goal was to see if this combination is safe and tolerable for people with advanced non-small cell lung cancer. Only 2 patients were enrolled before the study was terminated, so we have very limited information.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous tumor-infiltrating lymphocytes (GT201) plus teraplizumab
What this could lead to
If it works, this could point toward a new treatment option for advanced non-small cell lung cancer using a patient's own immune cells.
What could go wrong
This was a very small, early safety trial with only 2 participants and has already been terminated, so results are limited and may not apply to others. Risks include severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2 people

The number who actually took part.

Started

Feb 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Voluntarily join the study, signed informed consent form,, willing and able to comply with the study protocol; * 2\. Age 18 to 70 years old; * 3\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; * 4\. Expected survival time of ≥ 12 weeks; * 5\. Good function of vital organs; * 6\. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling; * 7\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling. Exclusion Criteria: * 1.Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry; * 2.Known mental illness, alcoholism, drug use or substance abuse; * 3.Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion; * 4.Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study; * 5.The investigators determine that other conditions that make the patient not suitable for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult Non-small cell lung cancer

Contacts and locations

Locations

  • Beijing Gobroad Hospital

    Beijing, Beijing Municipality, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, 200120, China

  • Shanghai GoBroad Cancer Hospital

    Shanghai, Shanghai Municipality, 200120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.